LTX-315 is under clinical development by Verrica Pharmaceuticals and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LTX-315’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LTX-315 overview

LTX-315 (Oncopore) is under development for the treatment of transdermally accessible tumors including malignant melanoma, head and neck squamous cell carcinoma, lymphoma, soft tissue sarcoma basal cell and squamous cell carcinomas. The drug is formulated as injection and administered through intratumoral route. LTX-315 (Oncopore) is a chemically modified cationic cytolytic nonapeptide which is equally active against drug-sensitive and drug-resistant cancer cells. It is derived from the naturally occurring antimicrobial peptide, bovine lactoferricin. It was also under development for carcinoma and liver cancer.

It was under development for the treatment of non-small cell lung cancer, urothelial carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma, Merkle cell carcinoma, small cell lung cancer, squamous cell carcinoma of esophagus, esophageal squamous cell carcinoma (ESCC), cervical cancer.

Verrica Pharmaceuticals overview

Verrica Pharmaceuticals (Verrica) is a biopharmaceutical company. It offers therapeutics for the treatment of skin diseases. The company offer products that include candidate, VP-102, a topical medication, is indicated for the treatment of Molluscum contagiosum and Verruca vulgaris (common warts). It is investigating YCANTH, a medication developed against Molluscum contagiosum; VP-102, targeting common and external genital warts; and VP-103, to cure Plantar warts. The company seeks to work in collaboration with pharmaceutical and biotechnology companies for the development commercialization of its products. Verrica is headquartered in West Chester, Pennsylvania, the US.

For a complete picture of LTX-315’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.